375 related articles for article (PubMed ID: 23696296)
1. The cellular mechanisms of dry eye: from pathogenesis to treatment.
Mantelli F; Massaro-Giordano M; Macchi I; Lambiase A; Bonini S
J Cell Physiol; 2013 Dec; 228(12):2253-6. PubMed ID: 23696296
[TBL] [Abstract][Full Text] [Related]
2. Effects of sequential artificial tear and cyclosporine emulsion therapy on conjunctival goblet cell density and transforming growth factor-beta2 production.
Pflugfelder SC; De Paiva CS; Villarreal AL; Stern ME
Cornea; 2008 Jan; 27(1):64-9. PubMed ID: 18245969
[TBL] [Abstract][Full Text] [Related]
3. Ocular surface and tear functions after topical cyclosporine treatment in dry eye patients with chronic graft-versus-host disease.
Wang Y; Ogawa Y; Dogru M; Kawai M; Tatematsu Y; Uchino M; Okada N; Igarashi A; Kujira A; Fujishima H; Okamoto S; Shimazaki J; Tsubota K
Bone Marrow Transplant; 2008 Feb; 41(3):293-302. PubMed ID: 17982500
[TBL] [Abstract][Full Text] [Related]
4. Preservation of tear film integrity and inhibition of corneal injury by dexamethasone in a rabbit model of lacrimal gland inflammation-induced dry eye.
Nagelhout TJ; Gamache DA; Roberts L; Brady MT; Yanni JM
J Ocul Pharmacol Ther; 2005 Apr; 21(2):139-48. PubMed ID: 15857280
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic Effects of STAT3 Inhibition on Experimental Murine Dry Eye.
Qu M; Qi X; Wang Q; Wan L; Li J; Li W; Li Y; Zhou Q
Invest Ophthalmol Vis Sci; 2019 Sep; 60(12):3776-3785. PubMed ID: 31503282
[TBL] [Abstract][Full Text] [Related]
6. Serine protease inhibitor A3K suppressed the formation of ocular surface squamous metaplasia in a mouse model of experimental dry eye.
Lin Z; Zhou Y; Wang Y; Zhou T; Li J; Luo P; He H; Wu H; Liu Z
Invest Ophthalmol Vis Sci; 2014 Aug; 55(9):5813-20. PubMed ID: 25103264
[TBL] [Abstract][Full Text] [Related]
7. The conjunctival epithelium in dry eye subtypes: effect of preserved and non-preserved topical treatments.
Albietz JM; Bruce AS
Curr Eye Res; 2001 Jan; 22(1):8-18. PubMed ID: 11402374
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of topical nerve growth factor treatment in dogs affected by dry eye.
Coassin M; Lambiase A; Costa N; De Gregorio A; Sgrulletta R; Sacchetti M; Aloe L; Bonini S
Graefes Arch Clin Exp Ophthalmol; 2005 Feb; 243(2):151-5. PubMed ID: 15650854
[TBL] [Abstract][Full Text] [Related]
9. Graft Versus Host Disease-Associated Dry Eye: Role of Ocular Surface Mucins and the Effect of Rebamipide, a Mucin Secretagogue.
Shamloo K; Barbarino A; Alfuraih S; Sharma A
Invest Ophthalmol Vis Sci; 2019 Nov; 60(14):4511-4519. PubMed ID: 31675422
[TBL] [Abstract][Full Text] [Related]
10. Effects of tear hyperosmolarity on conjunctival cells in mild to moderate dry eye.
Julio G; Lluch S; Pujol P; Merindano MD
Ophthalmic Physiol Opt; 2012 Jul; 32(4):317-23. PubMed ID: 22620852
[TBL] [Abstract][Full Text] [Related]
11. Reconsidering the central role of mucins in dry eye and ocular surface diseases.
Baudouin C; Rolando M; Benitez Del Castillo JM; Messmer EM; Figueiredo FC; Irkec M; Van Setten G; Labetoulle M
Prog Retin Eye Res; 2019 Jul; 71():68-87. PubMed ID: 30471351
[TBL] [Abstract][Full Text] [Related]
12. Effects of topical cyclosporine a plus artificial tears versus artificial tears treatment on conjunctival goblet cell density in dysfunctional tear syndrome.
Demiryay E; Yaylali V; Cetin EN; Yildirim C
Eye Contact Lens; 2011 Sep; 37(5):312-5. PubMed ID: 21792057
[TBL] [Abstract][Full Text] [Related]
13. Is the main lacrimal gland indispensable? Contributions of the corneal and conjunctival epithelia.
Stevenson W; Pugazhendhi S; Wang M
Surv Ophthalmol; 2016; 61(5):616-27. PubMed ID: 26968256
[TBL] [Abstract][Full Text] [Related]
14. Trehalose protects against ocular surface disorders in experimental murine dry eye through suppression of apoptosis.
Chen W; Zhang X; Liu M; Zhang J; Ye Y; Lin Y; Luyckx J; Qu J
Exp Eye Res; 2009 Sep; 89(3):311-8. PubMed ID: 19345212
[TBL] [Abstract][Full Text] [Related]
15. Topical administration of interleukin-1 receptor antagonist as a therapy for aqueous-deficient dry eye in autoimmune disease.
Vijmasi T; Chen FY; Chen YT; Gallup M; McNamara N
Mol Vis; 2013; 19():1957-65. PubMed ID: 24068863
[TBL] [Abstract][Full Text] [Related]
16. Effects of Quercetin in a Mouse Model of Experimental Dry Eye.
Oh HN; Kim CE; Lee JH; Yang JW
Cornea; 2015 Sep; 34(9):1130-6. PubMed ID: 26203745
[TBL] [Abstract][Full Text] [Related]
17. Experimental dry eye stimulates production of inflammatory cytokines and MMP-9 and activates MAPK signaling pathways on the ocular surface.
Luo L; Li DQ; Doshi A; Farley W; Corrales RM; Pflugfelder SC
Invest Ophthalmol Vis Sci; 2004 Dec; 45(12):4293-301. PubMed ID: 15557435
[TBL] [Abstract][Full Text] [Related]
18. Improvement of corneal barrier function by the P2Y(2) agonist INS365 in a rat dry eye model.
Fujihara T; Murakami T; Fujita H; Nakamura M; Nakata K
Invest Ophthalmol Vis Sci; 2001 Jan; 42(1):96-100. PubMed ID: 11133853
[TBL] [Abstract][Full Text] [Related]
19. An NGF mimetic, MIM-D3, stimulates conjunctival cell glycoconjugate secretion and demonstrates therapeutic efficacy in a rat model of dry eye.
Jain P; Li R; Lama T; Saragovi HU; Cumberlidge G; Meerovitch K
Exp Eye Res; 2011 Oct; 93(4):503-12. PubMed ID: 21726552
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of topical infliximab in a mouse model of experimental dry eye.
Li Z; Choi W; Oh HJ; Yoon KC
Cornea; 2012 Nov; 31 Suppl 1():S25-31. PubMed ID: 23038030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
